Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ambea ABCHIX:AMBEAS 81 3-Year EBITDA Growth Rate is 16.80% as of Mar. 2026, which is 21% below its 10-year median of 21.20. GuruFocus rates CHIX:AMBEAS with a GF Score™ of 81/100 and a GF Value™ of kr111.27 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 527 Healthcare Providers & Services companies, Ambea AB ranks better than 61.48% on this metric.
During the past 12 months, Ambea AB's average EBITDA Per Share Growth Rate was 15.80% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 16.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 16.80% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 24.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Ambea AB was 47.80% per year. The lowest was 10.90% per year. And the median was 21.20% per year.
Ambea AB (CHIX:AMBEAs) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Ambea AB 3-Year EBITDA Growth Rate Related Terms
CHIX:AMBEAS vs HCA, THC, DVA: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, Ambea AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ambea AB 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Ambea AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Ambea AB's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 16.80% mean?
Ambea AB (CHIX:AMBEAS) has a 3-Year EBITDA Growth Rate of 16.80% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ambea AB and its competitors. This is 21% below median its historical median of 21.20. Over the past decade, Ambea AB's 3-Year EBITDA Growth Rate has ranged from 10.90 to 47.80. According to the industry distribution chart, Ambea AB ranks #203 out of 527 companies in the Healthcare Providers & Services industry, placing it in the top 38.5%.
Is Ambea AB's 3-Year EBITDA Growth Rate too high?
Ambea AB's current 3-Year EBITDA Growth Rate of 16.80% is 21% below median its 10-year median of 21.20. Over the past 10 years, this metric has ranged from a low of 10.90 to a high of 47.80. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.20. Ambea AB's value of 16.80% is 64.7% above this industry median. Based on the distribution chart, Ambea AB ranks #203 out of 527 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Ambea AB has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ambea AB's 3-Year EBITDA Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Ambea AB ranks #203 out of 527 companies for 3-Year EBITDA Growth Rate. This puts Ambea AB in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.20. Ambea AB's value of 16.80% is 64.7% above this benchmark. Historically, Ambea AB's own 3-Year EBITDA Growth Rate has ranged from 10.90 to 47.80 over the past decade. While the company's 10-year median is 21.20 vs. the industry median of 10.20, Ambea AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 527 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ambea AB's current 3-Year EBITDA Growth Rate of 16.80% is 64.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ambea AB and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ambea AB's current 3-Year EBITDA Growth Rate is 16.80%, which is 21% below median its own 10-year median of 21.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ambea AB stock overvalued right now?
Based on GuruFocus' analysis, Ambea AB (CHIX:AMBEAS) is currently considered Modestly Overvalued. The stock's GF Value™ is kr111.27, compared to a current price of kr144.20 — trading 29.6% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 16.80%, which is 21% below median its 10-year median of 21.20 and 64.7% above the Healthcare Providers & Services industry median of 10.20. Ambea AB's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Ambea AB (CHIX:AMBEAS), the current 3-Year EBITDA Growth Rate is 16.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ambea AB (CHIX:AMBEAS) Overvalued in 2026?
Based on GuruFocus' analysis, Ambea AB stock appears to be overvalued.
The current stock price of kr144.20 is trading 29.6% above its estimated GF Value™ of kr111.27.
GuruFocus considers Ambea AB to be Modestly Overvalued.
Key valuation signals for CHIX:AMBEAS:
3-Year EBITDA Growth Rate: 16.80% (21% below median its 10-year median of 21.20)
GF Value™: kr111.27 vs. price of kr144.20 (29.6% above fair value)
Industry Position: 64.7% above the Healthcare Providers & Services median (#203 of 527)
No single metric tells the full story. See the CHIX:AMBEAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ambea AB is a Swedish care-provider group focused on elderly care, disability care, psychosocial support, housing, staffing, and training across the Nordic region. The company's segment includes: i) Nytida: Comprises social care services for children, youth and adults, in Sweden, ii) Vardaga: Comprises nursing homes and home care in Sweden, iii) Stendi: Comprises social care for children, youth and adult in Norway, iv) Validia: Comprises social care for children, v) Altiden: Comprises social care for children, youth and adults as well as elderly care in Denmark, and vi) Klara: Comprises competence and staffing solutions for elderly and social care, and student health services in Sweden. The majority of the company's revenue is derived from the Vardaga segment.
81GF Score
Get the complete analysis for CHIX:AMBEAS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:AMBEAS has been successfully added to your 
